PDCD1 and cancer: Furthermore, PD-1 and CTLA4 repression in T cells represent major obstacles to the efficacy of CAR-T treatment, and PD-1 and CTLA4 blockade by monoclonal antibodies have been intensively explored in cancer treatment (43).